2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
7
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Cervical Cancer Metastatic
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Recurrence
1
Non-squamous Non-small-cell Lung Cancer
1
Non Squamous Non Small Cell Lung
1
Neoplasms
1
Neoplasm Metastasis
1
Neoadjuvant Therapy
1
NSCLC
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
BRCA-Mutated Breast Carcinoma
1
Advanced Solid Tumor
1
Advanced NSCLC
1
Interventions
Pemetrexed
14
Carboplatin
13
osimertinib
11
aflutinib
9
Drug Therapy
9
Gefitinib
8
Radiotherapy
6
Docetaxel
6
Cisplatin
6
pembrolizumab
5
anlotinib
5
Radiosurgery
5
Paclitaxel
5
icotinib
4
Vinorelbine
4
Gemcitabine
4
Erlotinib Hydrochloride
4
tislelizumab
3
camrelizumab
3
apatinib
3
HM781-36B
3
toripalimab
2
spartalizumab
2
rezivertinib
2
dacomitinib
2
Tyrosine Kinase Inhibitors
2
Thalidomide
2
Surgical Procedures, Operative
2
S 1 (combination)
2
Platinum
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NSCLC
×
famitinib
×
Clear all
NCT05005468
2021-08-13
CAMFA-L
Shanghai Chest Hospital
Phase 2
Unknown
61 enrolled